Jay M. ("Marty") Tenenbaum is the founder and Chairman of CollabRx. Dr. Tenenbaum brings to CollabRx the unique perspective of a world-renowned Internet commerce pioneer and visionary. He was founder and CEO of Enterprise Integration Technologies, the first company to conduct a commercial Internet transaction (1992), secure Web transaction (1993) and Internet auction (1993). In 1994, he founded CommerceNet to accelerate business use of the Internet. In 1997, he co-founded Veo Systems, the company that pioneered the use of XML for automating business-to-business transactions. Dr. Tenenbaum joined Commerce One in January 1999, when it acquired Veo Systems. As Chief Scientist, he was instrumental in shaping the company's business and technology strategies for the Global Trading Web. Post Commerce One, Dr. Tenenbaum was an officer and director of Webify Solutions, which was sold to IBM in 2006, and Medstory, which was sold to Microsoft in 2007. Earlier in his career, Dr. Tenenbaum was a prominent AI researcher and led AI research groups at SRI International and Schlumberger Ltd. Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence, and a former consulting professor of Computer Science at Stanford. He currently serves as a director of Efficient Finance, Patients Like Me, and the Public Library of Science, and is a consulting professor of Information Technology at Carnegie Mellon's new West Coast campus. Dr. Tenenbaum holds B.S. and M.S. degrees in Electrical Engineering from MIT, and a Ph.D. from Stanford.

Rob Rodin is the Chairman and CEO of RDN Group; strategic advisors focused on corporate transitions, customer interface, sales and marketing, distribution and supply chain management. (Customers include: GM, GE, US Navy, Avnet, Siemens, Simon and Schuster). Additionally, he serves as Vice Chairman, Executive Director and Chairman of the Investment Committee of CommerceNet which researches and funds open platform, interoperable business services to advance commerce. Mr. Rodin served for over 10 years as CEO and President of Marshall Industries (NYSE: MI) a global, industrial, electronics distributor and supply chain management company with over $2 billion in sales. Information Week Magazine highlighted Marshall Industries as the "World's Number One Company in the Use of Technology", and CIO Magazine recognized Mr. Rodin as one of the "Top 100 Leaders for the New Millennium". UCLA presented Mr. Rodin with the "Information Systems Award for System Leadership" and the University of Connecticut presented him with the "Distinguished Alumni Award" and elected him to the "University Hall of Fame". Mr. Rodin's best selling book, "Free, Perfect and Now: Connecting to the Three Insatiable Customer Demands", chronicles the radical transformation of Marshall Industries. The changes he led have been taught as case studies at Harvard Business School, Columbia University, USC, MIT, and Stanford University. Mr. Rodin’s Board activities include: the Board of Directors of Napster (NAPS)(formally Roxio) as Chairman of the Compensation Committee and a Member of the Audit Committee, Vice Chairman of the Board of Directors of CommerceNet, Board Member / Director of supplyFX, Board Member / Director of ALS Therapy Development Institute, Board Member / Director and Member of the Governance and Nominating Committee of SM&A (NASDQ: WINS), Director of Inter-tel (NASDAQ: INTL), Advisory Board of LASEC (Los Angeles Sports and Entertainment Commission), Advisory Board of Electronics Supply & Manufacturing Magazine (CMP Publications), on the planning committee for Harvard and Stanford Presidents Seminars (YPO) and on University of Connecticut's School of Business Board of Advisors (Executive Council and Strategic Development Committee) as well as several private company advisory boards. Mr. Rodin formerly served on the Advisory Board of Distribution at USC, the Board of Directors of RosettaNet, as a Trustee of the W. Edwards Deming Institute, and President of NEDA’s (National Electronic Distribution Association) Education Foundation.

Barry Newman, Director
Barry Newman is a Venture Partner at NeoCarta Ventures. Mr. Newman has had a distinguished investment banking career which included: Vice Chairman of the Technology Group at Bear Stearns, the Head of Global Technology Corporate and Investment Banking for Banc of America Securities and its predecessor Nationsbanc Montgomery Securities, and head of Global Technology Corporate finance at Salomon Brothers and Salomon Smith Barney. Mr. Newman was a founder and served as CFO of Anthem Partners, a boutique merchant bank. Mr. Newman was also a principal at Odyssey Partners, a private equity and hedge fund organization and has served as CEO and CFO of several financial services and manufacturing organizations. Mr. Newman is a member of the MIT Visiting Committee on Student Life, the MIT Corporation Development Committee and the Dean's Strategic Council of the Stanford Law School. Mr. Newman holds Bachelor of Science degrees in both Chemical Engineering and Life Sciences from MIT, MBA and JD degrees from Stanford University and a Master of Laws (Taxation) from NYU.

John Curd has been the President and Chief Medical Officer at Threshold Pharmaceuticals since 2007. He had joined Threshold Pharmaceuticals as a member of the management team to lead the clinical development of product development candidates including Threshold's hypoxia activated prodrug, TH-302. Prior to Threshold Pharmaceuticals, Dr. Curd was President and Chief Medical Officer at Novacea, Inc. since 2001. He had served in senior roles at Maxygen and VaxGen, Inc. from June 1999 to December 2001, and Vice President of Clinical Development at Genentech, Inc. from December 1991 to June 1999. While at Genentech, he directed the clinical development of Herceptin®, Rituxan®, Xolair®, and Raptiva®. From 1978 to 1991, Dr. Curd served in various positions including President of the Medical Staff at Scripps Clinical and Research Foundation in La Jolla, California. Dr. Curd holds a B.S. in chemistry from Princeton University and an M.D. from Harvard Medical School.